Class 3 Obesity: when insurers say no, reviewers often say yes
In 18 published external-review decisions involving class 3 obesity, independent physician reviewers overturned the insurer’s denial 94.4% of the time.
Most-fought treatments for class 3 obesity
| Category | Decisions | Overturned |
|---|---|---|
| Zepbound | 6 | 100% |
| Wegovy Solution Auto-injector | 4 | 100% |
| Wegovy | 4 | 100% |
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. This patient presents with class 3 obesity, as well as weight-related comorbidities. The U.S. Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) for weight management in patients with obesity (body mass index (BMI) greater than 30 kg/m2) or who are overweight (BMI between 27 and 29.9 kg/m2 with at least one weight-related comorbidity), in addition to a reduced calorie diet and increased physical activity. The FDA approval of Zepbound is supported by medical trials which showed that in adults with obesity or excess weight, treatment with tirzepatide led to substantial and sustained weight loss as compared to treatment with placebo after 52 and 72 weeks.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. This patient presents with class 3 obesity, as well as weight-related comorbidities of hyperlipidemia and hypertension. The U.S. Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) for weight management in patients with obesity (body mass index (BMI) greater than 30 kg/m2) or who are overweight (BMI between 27 and 29.9 kg/m2 with at least one weight-related comorbidity), in addition to a reduced calorie diet and increased physical activity. The FDA approval of Zepbound is supported by medical trials which showed that in adults with obesity or excess weight, treatment with tirzepatide led to substantial and sustained weight loss as compared to treatment with placebo after 52 and 72 weeks.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Ozempic auto-injector pen. In this case, the patient has a history of class 3 obesity with a current body mass index (BMI) of 50.04 kg/m². He has multiple weight-related comorbidities, including prediabetes, hypertension, and hyperlipidemia. He has started caloric restriction and has been referred to a nutritionist. The U.S. Food and Drug Administration (FDA) approves the use of Ozempic (semaglutide) to lower blood sugar in patients with type 2 diabetes mellitus. Researchers report that clinical research showed that when Ozempic was added to other standard therapies for patients with a history of type 2 diabetes mellitus, these patients saw a substantial decrease in their A1C levels.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for class 3 obesity was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY